Pay in 4 interest-free payments of $7.40 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
Elevates approach is refreshingly transparent
As of mid-2025, retatrutide has not received marketing authorisation in the United Kingdom
You should delay a dose increase if you face any of the following: Severe nausea Vomiting more than twice in 24 hours Persistent stomach pain Symptoms of dehydration, like dark urine, dizziness, or a dry mouth Difficulty maintaining a regular eating routine Never adjust your dose on your own
Currently, there are other dual GIPR/GLP-1R agonists available, such as GLP-1R/GR (glucagon receptor), GLP-1R/AR (amylin receptor), and GLP-1R/NPYR (peptide YY binds to neuropeptide Y receptors) [36, 115] and even triple agonists that can activate GIPR to treat obesity and T2DM
:max_bytes(150000):strip_icc()/GettyImages-1807240274-2c7c39cb23f34a97bb2d8620911c343d.jpg)